Literature DB >> 6501549

Is borderline fasting hyperglycemia a risk factor for cardiovascular death?

E Barrett-Connor, D L Wingard, M H Criqui, L Suarez.   

Abstract

The majority of previously reported studies of borderline hyperglycemia as a risk factor for cardiovascular disease are based on post-challenge glucose levels, are limited to men, and show either no significant association or a possible threshold effect. In order to determine whether fasting plasma glucose (FPG) in the normal range (less than 140 mg/dl) predicts mortality, we prospectively studied a geographically defined Southern California community of 3625 nondiabetic men and women aged 40-79, 99.5% of whom were followed for 9 years. Levels of FPG were significantly associated with levels of most heart disease risk factors. After adjusting for these risk factors, FPG, analyzed either as a continuous or categorical variable, was independently and significantly associated with all-cause, cardiovascular and ischemic heart disease mortality in men in proportional hazard models. An excess of all-cause mortality with the highest levels of FPG (130-139 mg/dl) was the only statistically significant association seen in women. The absence of a significant linear association in women may reflect true sex differences or a lack of power owing to the relatively small numbers of deaths in women. The independent linear glucose mortality association in men found here differs from previous studies, and may reflect both the larger number of events and the use of FPG, which has less intra-individual variability and less potential for misclassification bias than post-challenge glucose.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6501549     DOI: 10.1016/0021-9681(84)90046-8

Source DB:  PubMed          Journal:  J Chronic Dis        ISSN: 0021-9681


  9 in total

1.  Joint British recommendations on prevention of coronary heart disease in clinical practice. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association.

Authors: 
Journal:  Heart       Date:  1998-12       Impact factor: 5.994

Review 2.  Strength training in the elderly: effects on risk factors for age-related diseases.

Authors:  B F Hurley; S M Roth
Journal:  Sports Med       Date:  2000-10       Impact factor: 11.136

3.  Post-meal coagulation activation in diabetes mellitus: the effect of acarbose.

Authors:  A Ceriello; C Taboga; L Tonutti; R Giacomello; L Stel; E Motz; M Pirisi
Journal:  Diabetologia       Date:  1996-04       Impact factor: 10.122

Review 4.  Effects of weight training on risk factors for coronary artery disease.

Authors:  B F Hurley; P F Kokkinos
Journal:  Sports Med       Date:  1987 Jul-Aug       Impact factor: 11.136

Review 5.  Occlusive vascular diseases in oral contraceptive users. Epidemiology, pathology and mechanisms.

Authors:  I F Godsland; U Winkler; O Lidegaard; D Crook
Journal:  Drugs       Date:  2000-10       Impact factor: 9.546

6.  Diabetes mellitus in Swedish middle-aged men. The study of men born in 1913 and 1923.

Authors:  L O Ohlson; B Larsson; H Eriksson; K Svärdsudd; L Welin; G Tibblin
Journal:  Diabetologia       Date:  1987-06       Impact factor: 10.122

7.  Asymptomatic hyperglycaemia and major ischaemic heart disease events in Britain.

Authors:  I J Perry; S G Wannamethee; P H Whincup; A G Shaper
Journal:  J Epidemiol Community Health       Date:  1994-12       Impact factor: 3.710

8.  A progressive increase in cardiovascular risk assessed by coronary angiography in non-diabetic patients at sub-diabetic glucose levels.

Authors:  Sven Schinner; Reiner Füth; Kerstin Kempf; Stephan Martin; Holger S Willenberg; Matthias Schott; Wilfried Dinh; Werner A Scherbaum; Mark Lankisch
Journal:  Cardiovasc Diabetol       Date:  2011-06-24       Impact factor: 9.951

Review 9.  Significant effects of mild endogenous hormonal changes in humans: considerations for low-dose testing.

Authors:  F Brucker-Davis; K Thayer; T Colborn
Journal:  Environ Health Perspect       Date:  2001-03       Impact factor: 9.031

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.